- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02677090
Fiber Tolerability in Children Aged 3-7 Year (Fiber - TIC)
Fiber Tolerability In Children Aged 3-7 Year
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of the trial is to determine, using a dose escalation design, the digestive tolerability of the PROMITOR®given at the doses of 6, then 9 and finally 12 g (corresponding to 4, 6, and 8 g of fibers respectively) twice a day with the meals of the morning and of the evening versus control (maltodextrin, no fiber) over one week of intake in children from 3 to 7 years old.
As it is an exploratory study there is no categorization between primary and secondary objectives.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Saint Herblain, France, 44800
- Biofortis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy children
- Aged between 3 and 7 years old
- Acceptance of the taste of the product
- Having breakfast on daily basis
- Consent and/or assent received according to regulation
- Informed consent of both parents/guardians (in respect with the French regulation)
- Parents/guardians affiliated to a health insurance (in respect with the French regulation)
Exclusion Criteria:
- Specific food regimen
- Intolerability or food allergy
- Antibiotic or any medication impacting the gut transit during the 2 weeks before the study
- Chronic gastrointestinal disease
- Gastroenteritis in the 2 weeks preceding the study
- Constipation or diarrhea based on ROMEIII criteria (in average: more than 3 stools per day or less than 3 stools per week)
- Children and parents expected not to understand and perform the trial correctly (i.e.: troubles in learning and/or speaking)
- Child in a situation which, in the opinion of the principal investigator, could interfere with the optimal participation to the study or constitute a particular risk of non-compliance
- Having participated in another clinical trial for 1 month, or currently participating in a clinical trial
- Under legal protection or deprived from his rights following administrative or judicial decision (in respect with the French regulation)
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
|
ACTIVE_COMPARATOR: Dose 1 - Promitor®
Investigational product Dose 1
|
|
ACTIVE_COMPARATOR: Dose 2 - Promitor®
Investigational product Dose 2
|
|
ACTIVE_COMPARATOR: Dose 3 - Promitor®
Investigational product Dose 3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the digestive tolerability of the Investigational Product (abdominal pain) using analog visual scale
Time Frame: 7 days of intake
|
Using analog visual scale
|
7 days of intake
|
Assessment of the digestive tolerability of the Investigational Product (rumbling) using analog visual scale
Time Frame: 7 days of intake
|
Using analog visual scale
|
7 days of intake
|
Assessment of the digestive tolerability of the Investigational Product (bloating) using analog visual scale
Time Frame: 7 days of intake
|
Using analog visual scale
|
7 days of intake
|
Assessment of the digestive tolerability of the Investigational Product (flatulence) using analog visual scale
Time Frame: 7 days of intake
|
Using analog visual scale
|
7 days of intake
|
Assessment of the digestive tolerability of the Investigational Product (stools consistency & frequency) using analog visual scale
Time Frame: 7 days of intake
|
Using analog visual scale
|
7 days of intake
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15.10.NRC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Signs and Symptoms, Digestive
-
Seed HealthCurebase Inc.CompletedConstipation | Signs and Symptoms | Digestive Signs and Symptoms | Infrequent or Difficult EvacuationUnited States
-
AB Biotics, SACompleted
-
Kyowa Kirin Pharmaceutical Development LtdCompletedConstipation, Signs and Symptoms, DigestiveUnited Kingdom, Denmark, Norway, Israel, Spain
-
Children's Mercy Hospital Kansas CityTerminated
-
Centers for Disease Control and PreventionProcter and Gamble; Health Oriented Preventive EducationCompleted
-
U.S. Army Medical Research and Development CommandWithdrawnDiarrheaUnited States
-
Forest LaboratoriesCompleted
-
University of MalayaSecond Affiliated Hospital, School of Medicine, Zhejiang University; Zhejiang...Unknown
-
Microbiome Health SciencesCompleted
Clinical Trials on Placebo (including Maltodextrin)
-
NestléCompleted
-
Federal University of Health Science of Porto AlegreCompletedFatigue | Exercise-induced Muscle DamageBrazil
-
University of OxfordNational Health and Medical Research Council, Australia; Monash University; Oxford... and other collaboratorsUnknownAnxiety | Magnetic Resonance Imaging | Decision Making | Cortisol | Humans | Emotion | PrebioticsUnited Kingdom
-
University of Illinois at Urbana-ChampaignRecruitingOverweight and ObesityUnited States
-
Quark PharmaceuticalsCompletedGlaucoma, Angle-closure, Primary, AcuteSingapore, United States, Vietnam
-
Merck KGaA, Darmstadt, GermanyTerminatedSupratentorial Newly Diagnosed Inoperable GliobastomaGermany
-
University of Maryland, BaltimoreNational Center for Complementary and Integrative Health (NCCIH)RecruitingSchizophrenia | Schizoaffective DisorderUnited States
-
Mahidol UniversityCompletedQuality of Life | Cirrhosis | Muscle CrampThailand
-
Maastricht University Medical CenterCompletedObesity | Change of Transit or Circulation